Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study

医学 托法替尼 耐受性 内科学 不利影响 关节炎 痹症科 外科 类风湿性关节炎
作者
Hermine I. Brunner,Jonathan Akikusa,Eslam Al‐Abadi,John F. Bohnsack,Alina Boteanu,Gaëlle Chédeville,Rubén Cuttica,Wendy de la Pena,Lawrence Jung,Ela Tarakçı,Katarzyna Kobusińska,Grant S. Schulert,Cláudia Lopes Santoro Neiva,Rafael Rivas‐Chacon,Juan Cruz Rizo Rodriguez,Mónica Vázquez-Del Mercado,Linda Wagner‐Weiner,Jennifer E. Weiss,Carine Wouters,Holly Posner,Ann Wouters,Cheng Chang,Claire White,Keith S. Kanik,Shixue Liu,Alberto Martini,Daniel J. Lovell,Nicolino Ruperto
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:: ard-225094 被引量:1
标识
DOI:10.1136/ard-2023-225094
摘要

Objectives We report the safety, tolerability and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) in an ongoing long-term extension (LTE) study. Methods Patients (2–<18 years) with JIA who completed phase 1/3 index studies or discontinued for reasons excluding treatment-related serious adverse events (AEs) entered the LTE study and received tofacitinib 5 mg two times per day or equivalent weight-based doses. Safety outcomes included AEs, serious AEs and AEs of special interest. Efficacy outcomes included improvement since tofacitinib initiation per the JIA-American College of Rheumatology (ACR)70/90 criteria, JIA flare rate and disease activity measured by Juvenile Arthritis Disease Activity Score (JADAS)27, with inactive disease corresponding to JADAS ≤1.0. Results Of 225 patients with JIA (median (range) duration of treatment, 41.6 (1–103) months), 201 (89.3%) had AEs; 34 (15.1%) had serious AEs. 10 patients developed serious infections; three had herpes zoster. Two patients newly developed uveitis. Among patients with polyarticular course JIA, JIA-ACR70/90 response rates were 60.0% (78 of 130) and 33.6% (47 of 140), respectively, at month 1, and generally improved over time. JIA flare events generally occurred in <5% of patients through to month 48. Observed mean (SE) JADAS27 was 22.0 (0.6) at baseline, 6.2 (0.7) at month 1 and 2.8 (0.5) at month 48, with inactive disease in 28.8% (36 of 125) of patients at month 1 and 46.8% (29 of 82) at month 48. Conclusions In this interim analysis of LTE study data in patients with JIA, safety findings were consistent with the known profile of tofacitinib, and efficacy was maintained up to month 48. Trial registration number NCT01500551 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
别闹闹发布了新的文献求助10
3秒前
幸运星发布了新的文献求助10
3秒前
CipherSage应助mark采纳,获得10
5秒前
pluto应助从容的香菇采纳,获得10
5秒前
科研通AI5应助cccyq采纳,获得10
6秒前
科研狗完成签到,获得积分10
8秒前
英俊的铭应助gs19960828采纳,获得10
9秒前
MrTStar完成签到 ,获得积分10
11秒前
淡定的惜完成签到,获得积分20
14秒前
完美世界应助fengliurencai采纳,获得10
19秒前
思源应助大面包采纳,获得10
20秒前
sandra完成签到 ,获得积分10
21秒前
iris601完成签到,获得积分10
23秒前
时笙发布了新的文献求助30
25秒前
温柔的迎荷完成签到,获得积分10
27秒前
量子星尘发布了新的文献求助10
29秒前
30秒前
30秒前
传奇3应助快乐一江采纳,获得10
31秒前
传统的纸飞机完成签到 ,获得积分10
31秒前
31秒前
31秒前
王子安应助lilila666采纳,获得10
33秒前
大面包发布了新的文献求助10
34秒前
情怀应助漫山采纳,获得10
35秒前
zzz完成签到,获得积分10
36秒前
gs19960828发布了新的文献求助10
37秒前
幸福大白发布了新的文献求助30
37秒前
脑洞疼应助jbhb采纳,获得10
41秒前
41秒前
gs19960828完成签到,获得积分10
42秒前
Younglee完成签到,获得积分10
46秒前
46秒前
xiaoxuan完成签到,获得积分10
47秒前
48秒前
Garnieta完成签到,获得积分10
49秒前
彤光赫显发布了新的文献求助10
50秒前
50秒前
浔城游侠完成签到,获得积分10
51秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989406
求助须知:如何正确求助?哪些是违规求助? 3531522
关于积分的说明 11254187
捐赠科研通 3270174
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174